Drug
Valbenazine
Valbenazine: highest development phase Post-Market, developed by Neurocrine Biosciences. 13 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Valbenazine NCT05859698 | Post-Market | Schizophrenia |
| Valbenazine NCT03698331 | Post-Market | Tardive Dyskinesia (TD) |
| Valbenazine NCT07105111 | Post-Market | Schizophrenia |
| Valbenazine NCT06312189 | Phase 3 | Chorea, Huntington |
| Valbenazine NCT05110157 | Phase 3 | Schizophrenia |
| Valbenazine NCT05206513 | Phase 3 | Dyskinesia |
| Valbenazine NCT02736955 | Phase 3 | Tardive Dyskinesia |
| Valbenazine NCT04400331 | Phase 3 | Chorea, Huntington |
| Valbenazine NCT03530293 | Phase 2 | Tourette Syndrome |
| Valbenazine NCT07111988 | Phase 2 | Obsessive-Compulsive Disorder |
| Valbenazine NCT03325010 | Phase 2 | Tourette Syndrome |
| Valbenazine NCT02879578 | Phase 2 | Tourette Syndrome |
| Valbenazine NCT05053321 | Phase 1 | Tardive Dyskinesia |
Latest
No recent events.
Follow Valbenazine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.